



ADULT MEDICATION GUIDELINE

Prazosin

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and
Breastfeeding](#)

Restrictions

[Formulary: Unrestricted](#)

Medication Class

Alpha-blocker (selective)

Presentation

Form: 1mg, 2mg, 5mg

Storage

Store at room temperature, below 25°C

Dose

Hypertension

Oral:

Initially 0.5mg twice daily. Increase slowly to 1mg two or three times daily. Maintenance dose 3-20mg in 2 or 3 divided doses.

Administration

Oral

Take with or without food

Monitoring

First dose effect – orthostatic hypotension (increase dose slowly to avoid)

Pregnancy

1st Trimester: Consider alternative

2nd Trimester: Monitoring required

3rd Trimester: Monitoring required

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Consider alternative

For more information, please contact [KEMH Obstetric Medicines Information Service](#).









Related Policies, Procedures & Guidelines

[Hypertension in pregnancy: Medical management](#)

References

Australian Medicines Handbook. Prazosin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 July 20]. Available from: <https://amhonline.amh.net.au/>

The Royal Women's Hospital. Prazosin. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 July 20]. Available from: <https://thewomenspbmg.org.au/>

Keywords	Prazosin, alpha blocker, HTN, hypertension, antihypertensive, blood pressure, minipress				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	02/2015	Last Reviewed:	Aug 2021	Review Date:	Nov 2024
Endorsed by:	Medicines and Therapeutics Committee			Date:	02/11/2021
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2021

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.